Navigation Links
Trius Therapeutics Obtains Special Protocol Assessment With FDA for Phase 3 Study of Torezolid Phosphate
Date:6/16/2010

SAN DIEGO, June 16 /PRNewswire/ -- Trius Therapeutics, Inc. announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study for the oral dosage form of torezolid phosphate for treatment of acute bacterial skin and skin structure infections (ABSSSI).  The double-blind pivotal study will compare the efficacy and safety of once-daily oral administration of 200 milligrams of torezolid phosphate over six days of treatment to twice-daily oral administration of 600 milligrams of linezolid (Zyvox) for 10 days of treatment. The primary efficacy endpoint will be the cessation of spread of infected lesions and absence of fever at 48 to 72 hours following initiation of treatment. Secondary endpoints will include, among other things, sustained clinical response at the end of therapy visit, and the investigator's assessment of clinical response at all visits and clinical success at the post treatment evaluation visit. Provided non-inferiority is met, an assessment of superiority of torezolid phosphate to linezolid with respect to the primary efficacy endpoint will also be made.

Special Protocol Assessment

The SPA process creates a written agreement between the FDA and a sponsor concerning the clinical trial design, clinical endpoints and other clinical trial issues that can be used to support regulatory approval of a drug candidate. The process is intended to provide assurance that if the agreed upon clinical trial protocols are followed, the clinical trial endpoints are achieved and there is a favorable risk benefit profile, the data may serve as the primary basis of an efficacy claim in support of a New Drug Application (NDA).

About Trius Therapeutics'/>"/>

SOURCE Trius Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
2. PacificGMP Completes GMP Product Fill for Trius Therapeutics
3. Trius Doses First Patient in Antibacterial Phase 2 Trial
4. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
5. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
6. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
7. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
8. Trius Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting
9. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
10. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
11. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - a ... to place and insert the screw accurately - offers ... ligament) repair or reconstruction as it holds the bones ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw ...
(Date:1/14/2014)... 2014   NuAire , a manufacturer of ergonomically designed laboratory ... Koki of Japan to sell and ... . NuAire will utilize its network of sales professionals throughout ... to offer assistance in application use, product benefits and ...
(Date:1/14/2014)... N.Y. , Jan. 14, 2014   Oligomerix, Inc. , ... modifying therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... to Valhalla, NY as of ... laboratory space at New York Medical College. ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... senior health policy analyst for Consumers Union, will urge Congress ... before the House Energy & Commerce Health Subcommittee.  The ... of the Medical Device User Fee Act beginning at 10:15 ... Recent safety problems with metal hip implants ...
... LA JOLLA, Calif., Feb. 15, 2012 Celladon ... and development of innovative treatments for cardiovascular diseases, ... million equity financing to advance its lead investigational ... failure. The financing was led by new investor ...
Cached Medicine Technology:Consumers Union to Testify for Stronger Medical Device Safety Oversight at House Hearing Today 2Consumers Union to Testify for Stronger Medical Device Safety Oversight at House Hearing Today 3Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure 2Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure 3
(Date:7/9/2014)... Australian researchers reveal that sudden, acute episodes of low ... as temperature, humidity, air pressure, wind direction and precipitation. ... a journal of the American College of Rheumatology (ACR), ... increases with higher wind speed or wind gusts, but ... World Health Organization (WHO) nearly everyone experiences low back ...
(Date:7/9/2014)... School of Medicine at the University of Pennsylvania in ... an $8 million grant from the National Cancer Institute ... (PDT) in patients with malignant pleural mesothelioma, a rare, ... in the lining of the lungs and is caused ... fund a clinical trial and additional studies looking at ...
(Date:7/9/2014)... that captures heretofore hidden ways that cells are regulated, ... makes breast cancer cells more likely to metastasize. , ... in part by blocking two other proteins that are ... two disease processes could have unexpected ties. , ... of Nature , points to the possibility of ...
(Date:7/9/2014)... Center paint a relatively optimistic picture of women,s chances ... spread to the chest wall or skin, but not ... regardless of size and whether they have involved lymph ... called "locally advanced" tumors, suggesting that they are a ... Locally advanced breast cancers of this and other types ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2
... Ph.D., a senior research scientist in the Department of ... Park, has been chosen to receive a 2009 Astellas ... Chemical Society, is given to individuals who have made ... their work in the chemical and related sciences. ...
... ... Carestream Health will Share Insights and Best Practices for Developing an Intelligent Portfolio ... Austin, Texas ... management solutions, will host a case study webinar discussing best practices for increasing ...
... , U.S. Rep. ... , WASHINGTON, Dec. 10 The Federal Employees Health Benefits ... American Federation of Government Employees, (AFGE) "Inside Government" radio program. The ... on Federal News Radio at www.federalnewsradio.com ...
... Speaker Nancy Pelosi issued the following statement today applauding ... Appropriations Act lifting the ban on federal funding for syringe ... bill passed the House this afternoon by a vote of ... syringe exchange could not be more clear. As Dr. Anthony ...
... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced that ... Morgan Healthcare Conference on Monday, January 11, 2010 at 2:30 p.m. ... Francis Hotel in San Francisco, CA. , Individuals can ... section of the company,s web site www.savient.com . Following ...
... may help avert drug errors, study authors suggest, , ... finds that even adults who know what medicines they ... getting in the hospital. , Forty-four percent of patients ... that was not actually prescribed. A patient who normally ...
Cached Medicine News:Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 2Health News:Planview and Carestream Health Discuss the Intelligent Portfolio on December 17 Webinar 3Health News:FEHBP Open Enrollment Period to be Discussed on Special Rebroadcast of 'Inside Government' 2Health News:Pelosi: Lifting the Ban on Federal Funding for Syringe Exchange is a Victory for Science and for Public Health 2Health News:Most Hospital Patients Don't Know What Meds They're Taking 2Health News:Most Hospital Patients Don't Know What Meds They're Taking 3
... Delivers the advanced performance benefits ... strength, versatility, and durability ... that augments the effectiveness of ... floor reconstruction. Comprised of sterile, ...
... (also known as the VOCARE) Bladder System ... used by people with spinal cord injuries ... demand. A secondary use of the device ... promote penile erection.,The Bladder System includes surgically ...
Used for dilation of a tract to the kidney for removal of stones. Supplied sterile in peel-open packages. Intended for one-time use....
... Urinary Control offers a revolutionary approach ... symptoms of overactive bladder, including urinary ... urgency-frequency alone or in combination in ... not tolerate more conservative treatments. Medtronic ...
Medicine Products: